ESTRO 2024 - Abstract Book

S2796

Interdisciplinary - Health economics & health services research

ESTRO 2024

Results:

From 2017 until 2022, 1886 consecutive breast cancer patients were irradiated using moderate hypofractionation. The number of breast cancer patients treated with moderate hypofractionation radiotherapy was 1,7 times higher than those treated with normal fractionation in the years 2011-2016. 44% of the patients lived in capital and 66% in other cities of the country. The median driving distance and transit time was 68.5 km (range 3-264km) and 68min (range 7-253min) respectively. Breast cancer patients treated at our department avoided a median of 679km and 690min from the use of moderated hypofractionation. Reducing the number of fractions per treatment resulted in a 27% reduction in the costs of radiotherapy treatment and a 40% reduction in transit time, and hospitalization costs.

Conclusion:

The moderate hypofractionation radiotherapy increased the number of breast cancer patients treated at our department and reduced the costs of irradiation and hospitalization. It also reduced the driving distance and time needed for patients to receive radiotherapy making it more convenient. The increased number of treated patients suggests towards breast conservation which is still at low levels in our country.

Keywords: Hypofractionation, Cost, Breast cancer

1089

Digital Poster

Prostate cancer care in the Middle East and North Africa: a comprehensive practice survey

Fanar Al-Samarat 1 , Anas Alrawashdeh 2 , Raneem Ibrahim 1 , Sami Khatib 3 , Khaled Alrawashdeh 4 , Ahmed Salem 1,5,6

1 The Hashemite university, Department of Anatomy, Physiology and Biochemistry, Zraqa, Jordan. 2 The Hashemite university, Faculty of Medicine, Zraqa, Jordan. 3 Afia Radiotherapy and Nuclear Medicine Center, radiation oncologiest, Amman, Jordan. 4 Royal Shrewsbury hospital, Oncology department, Shrewsbury, United Kingdom. 5 University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom. 6 Christie NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom

Purpose/Objective:

Prostate cancer is the second most common cancer and the fifth leading cause of cancer mortality in men worldwide (1). Prostate cancer is categorized into prognostic groups according to the results of prostate biopsy (Gleason score), prostate-specific antigen (PSA) at diagnosis and tumor stage (2). Treatment options are informed based on the cancer risk group and the patient’s general health (2). The purpose of this study is to quantify current prostate cancer care practices in the Middle East and North Africa (MENA) to identify areas for improvement in the diagnosis and treatment while assessing how closely the current practices align with international practice guidelines